Addition Therapeutics
PrivateLast Round
Series A
Extension
Dec 22, 2025
Total Funding Raised
$106M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Addition Therapeutics is a biotechnology company developing a new class of genomic medicines using its all-RNA, non-viral, LNP-based PRINT (Precise RNA-Mediated Insertion of Transgenes) platform to create one-time therapies for chronic and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Addition Therapeutics Comparables
Compare Addition Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fractyl Health | 77% | |
| Remedium Bio | 77% | |
| Amgen | 67% |
Addition Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 22, 2025 | ||||
| Series A | Sep 1, 2023 |
Addition Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BEVC | Series A, Series A Extension |
| Gates Family Foundation | Series A Extension |
| Osage University Partners | Series A, Series A Extension |
| Gates Foundation | Series A Extension |
| Abingworth | Series A, Series A Extension |
| Bill & Melinda Gates Foundation | Series A, Series A Extension |
| Pivotal bioVenture Partners | Series A, Seed, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2026
Developing a gene therapy for permanent GLP-1 production in liver cells.
- Dec 22, 2025
$100M Series A round completed.
Addition Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Addition Therapeutics's valuation, stock price, and market status.
Is Addition Therapeutics a public or private company?
Addition Therapeutics is a private company.
What is the current stock price of Addition Therapeutics?
Addition Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Addition Therapeutics worth (valuation)?
Valuation information for Addition Therapeutics is not publicly available.
Can I buy Addition Therapeutics stock?
Addition Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Addition Therapeutics's last funding round?
Addition Therapeutics's most recent funding round was Series A on December 17, 2025.
Who are the main investors in Addition Therapeutics?
Key investors in Addition Therapeutics include Pivotal bioVenture Partners.
Will Addition Therapeutics IPO soon?
No public IPO plans have been announced for Addition Therapeutics.
How can I track Addition Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Addition Therapeutics's secondary market activity and sign up for updates.